secwatch / observer
8-K filed May 30, 2025, 7:59 PM ET ticker ADIL CIK 0001513525
regulatory confidence high sentiment negative materiality 0.75

ADIAL PHARMACEUTICALS, INC. (ADIL): Nasdaq/NYSE listing notice — Adial Pharmaceuticals receives Nasdaq delisting notice for equity below $2.5M minimum

ADIAL PHARMACEUTICALS, INC.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.97

ADIAL PHARMACEUTICALS, INC. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange
nasdaq
Notice
noncompliance notice
Deficiency
stockholders equity
Rules
5550(b)(1)
Exact text from the filing
May 23, 2025, Adial Pharmaceuticals, Inc. (the “Company”), received a letter from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) because the stockholders’ equity of the Company of $2,126,662 as of March 31, 2025, as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 14, 2025, was below the minimum requirement of $2,500,000. As of the date of this Current Report on Form 8-K, the Company does not have a market value of listed securities of $35 million, or net income from continued o
View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR
accession 0001213900-25-049451
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.